NZyme Pharmaceuticals

N-Zyme Biomedical is a clinical-stage biopharmaceutical company focused on developing the first targeted treatments for reflux disorders, specifically Laryngopharyngeal Reflux (LPR) and Gastroesophageal Reflux Disease (GERD). The company's lead program, NZYM-001, is a repurposed formulation of the HIV protease inhibitor fosamprenavir, which has been discovered to act as a potent pepsin inhibitor. By targeting pepsin—the primary agent of tissue damage in the upper aerodigestive tract—N-Zyme aims to provide relief for patients who are unresponsive to traditional proton pump inhibitors (PPIs). The company is currently advancing its pipeline through Phase 2 proof-of-concept clinical trials and is exploring both oral and aerosolized delivery methods.